<?xml version="1.0" encoding="UTF-8"?>
<search_results count="1046">
  <query>SEARCH[STUDY] ( Crohn's Disease [STUDY:ALL-FIELDS] )</query>
  <clinical_study>
    <order>301</order>
    <score>0.90716</score>
    <nct_id>NCT00078611</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00078611</url>
    <title>A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: natalizumab</intervention_summary>
    <last_changed>June 14, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>302</order>
    <score>0.90701</score>
    <nct_id>NCT02193048</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02193048</url>
    <title>Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: This study will evaluate a new clinical scoring system in patients receiving routine treatment</intervention_summary>
    <last_changed>April 11, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>303</order>
    <score>0.90697</score>
    <nct_id>NCT01696396</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01696396</url>
    <title>AMG 181 in Subjects With Moderate to Severe Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: AMG 181; Other: Placebo</intervention_summary>
    <last_changed>June 8, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>304</order>
    <score>0.90672</score>
    <nct_id>NCT02000362</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02000362</url>
    <title>Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Stem cells</intervention_summary>
    <last_changed>October 5, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>305</order>
    <score>0.90669</score>
    <nct_id>NCT01580670</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01580670</url>
    <title>Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Pediatric Crohn's Disease</condition_summary>
    <intervention_summary>Drug: TA-650</intervention_summary>
    <last_changed>April 9, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>306</order>
    <score>0.9066</score>
    <nct_id>NCT00250198</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00250198</url>
    <title>The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: STA-5326</intervention_summary>
    <last_changed>June 30, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>307</order>
    <score>0.90655</score>
    <nct_id>NCT02367183</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02367183</url>
    <title>A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: GED-0301; Drug: Placebo</intervention_summary>
    <last_changed>June 21, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>308</order>
    <score>0.90652</score>
    <nct_id>NCT01698970</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01698970</url>
    <title>Effect of the Consumption of a Probiotic Strain on the Prevention of Post-operative Recurrence in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: 1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test); Other: 2- excipients (150 mg) in capsule (control)</intervention_summary>
    <last_changed>December 6, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>309</order>
    <score>0.90649</score>
    <nct_id>NCT00495521</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00495521</url>
    <title>High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: PASER or placebo granules</intervention_summary>
    <last_changed>October 19, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>310</order>
    <score>0.90638</score>
    <nct_id>NCT02631967</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02631967</url>
    <title>Surgical Prevention of Anastomotic Recurrence by Excluding Mesentery in Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Procedure: Kono anastomosis; Procedure: Stapled side-to-side anastomosis</intervention_summary>
    <last_changed>February 13, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>311</order>
    <score>0.90633</score>
    <nct_id>NCT00862121</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00862121</url>
    <title>A Study With Pentasa in Patients With Active Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn´s Disease</condition_summary>
    <intervention_summary>Drug: Pentasa; Drug: Placebo</intervention_summary>
    <last_changed>March 15, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>312</order>
    <score>0.9063</score>
    <nct_id>NCT02038920</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02038920</url>
    <title>Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab; Drug: Vedolizumab placebo</intervention_summary>
    <last_changed>July 28, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>313</order>
    <score>0.90622</score>
    <nct_id>NCT00609752</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00609752</url>
    <title>Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: prednisolone; Dietary Supplement: Alicalm (polymeric liquid formula)</intervention_summary>
    <last_changed>December 29, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>314</order>
    <score>0.906</score>
    <nct_id>NCT00257699</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00257699</url>
    <title>Study of Antibiotics in the Treatment of Colonic Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Metronidazole placebo; Drug: ciprofloxacin placebo; Drug: ciprofloxacin; Drug: metronidazole</intervention_summary>
    <last_changed>August 11, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>315</order>
    <score>0.90592</score>
    <nct_id>NCT01692808</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01692808</url>
    <title>Bioavailability of Vitamin D in Children and Adolescents With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vitamin D3 3000 UI daily; Drug: Vitamin D3 4000 UI daily</intervention_summary>
    <last_changed>November 2, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>316</order>
    <score>0.9058</score>
    <nct_id>NCT01823042</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01823042</url>
    <title>The Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD)</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: azathioprine+enteral nutrition; Drug: Azathioprine</intervention_summary>
    <last_changed>March 28, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>317</order>
    <score>0.90578</score>
    <nct_id>NCT00348283</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00348283</url>
    <title>Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: adalimumab; Biological: placebo; Biological: adalimumab</intervention_summary>
    <last_changed>April 7, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>318</order>
    <score>0.90548</score>
    <nct_id>NCT00445432</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00445432</url>
    <title>A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: adalimumab; Other: Placebo</intervention_summary>
    <last_changed>February 1, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>319</order>
    <score>0.90548</score>
    <nct_id>NCT01388933</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01388933</url>
    <title>A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: TU-100; Drug: Matching Placebo</intervention_summary>
    <last_changed>May 18, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>320</order>
    <score>0.90533</score>
    <nct_id>NCT01514240</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01514240</url>
    <title>Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: D9421-C capsule 3 mg; Drug: Mesalazine tablets</intervention_summary>
    <last_changed>September 8, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>321</order>
    <score>0.90528</score>
    <nct_id>NCT00764699</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00764699</url>
    <title>Effect of Increlex® on Children With Crohn Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: rhIGF (Increlex)</intervention_summary>
    <last_changed>May 14, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>322</order>
    <score>0.90519</score>
    <nct_id>NCT01769755</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01769755</url>
    <title>A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohns Disease</condition_summary>
    <intervention_summary>Biological: PDA001; Drug: Vehicle Controlled Placebo</intervention_summary>
    <last_changed>August 17, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>323</order>
    <score>0.90476</score>
    <nct_id>NCT00056355</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00056355</url>
    <title>Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: UVADEX and UVAR XTS Photopheresis System</intervention_summary>
    <last_changed>March 3, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>324</order>
    <score>0.90461</score>
    <nct_id>NCT00672763</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00672763</url>
    <title>Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Colecalciferol D3 (Vigantol Oil); Drug: Medium chain triglycerides</intervention_summary>
    <last_changed>June 3, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>325</order>
    <score>0.90453</score>
    <nct_id>NCT00265122</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00265122</url>
    <title>A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Ustekinumab 90 mg; Drug: Ustekinumab 4.5 mg/kg; Drug: Placebo SC; Drug: Placebo IV</intervention_summary>
    <last_changed>January 20, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>326</order>
    <score>0.9041</score>
    <nct_id>NCT02193802</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02193802</url>
    <title>Role of Capsule Endoscopy in the Evaluation of Mucosal Changes During Treatment of Patients With Active Crohn's Disease</title>
    <status open="N">Suspended</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Device: PillCam® SB3 capsules</intervention_summary>
    <last_changed>April 26, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>327</order>
    <score>0.90404</score>
    <nct_id>NCT01183403</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01183403</url>
    <title>CE-U and MRE to Predict the Efficacy of Anti-TNF Therapy in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>June 21, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>328</order>
    <score>0.90384</score>
    <nct_id>NCT01277666</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01277666</url>
    <title>A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: GSK1605786A; Drug: GSK1605786A; Drug: Placebo</intervention_summary>
    <last_changed>January 9, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>329</order>
    <score>0.9037</score>
    <nct_id>NCT02465944</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02465944</url>
    <title>A Pilot Study of FFP104 in Subjects With Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: FFP104; Drug: Placebo</intervention_summary>
    <last_changed>August 23, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>330</order>
    <score>0.90358</score>
    <nct_id>NCT01261286</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01261286</url>
    <title>Drug-Disease Interaction in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: verapamil</intervention_summary>
    <last_changed>December 14, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>331</order>
    <score>0.90298</score>
    <nct_id>NCT03078803</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03078803</url>
    <title>Fecal Transplant for Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Biological: Fecal Microbiota Transplant (FMT); Biological: Placebo</intervention_summary>
    <last_changed>May 1, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>332</order>
    <score>0.90287</score>
    <nct_id>NCT00774982</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00774982</url>
    <title>Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Crohns Disease</condition_summary>
    <intervention_summary>Drug: Delayed Release 6 mercaptopurine; Drug: 6 Mercaptopurine</intervention_summary>
    <last_changed>July 16, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>333</order>
    <score>0.90273</score>
    <nct_id>NCT02578576</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02578576</url>
    <title>The Diagnostic Methods of Early Postoperative Flare-up of Crohn's Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>October 16, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>334</order>
    <score>0.90264</score>
    <nct_id>NCT02649075</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02649075</url>
    <title>To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Serum-derived Bovine Immunoglobulin / Protein Isolate; Other: Placebo</intervention_summary>
    <last_changed>July 5, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>335</order>
    <score>0.90261</score>
    <nct_id>NCT00329420</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00329420</url>
    <title>Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Certolizumab pegol; Biological: Certolizumab pegol; Biological: Certolizumab pegol</intervention_summary>
    <last_changed>February 27, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>336</order>
    <score>0.90231</score>
    <nct_id>NCT00946946</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00946946</url>
    <title>Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Azathioprine; Drug: Mesalazine; Drug: Azathioprine placebo; Drug: Mesalazine placebo</intervention_summary>
    <last_changed>June 25, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>337</order>
    <score>0.90221</score>
    <nct_id>NCT02538354</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02538354</url>
    <title>The Effect of Riboflavin in Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Riboflavin supplementation</intervention_summary>
    <last_changed>May 25, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>338</order>
    <score>0.9022</score>
    <nct_id>NCT01279577</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01279577</url>
    <title>Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn´s Disease</condition_summary>
    <intervention_summary>Drug: Low dose TSO; Drug: Medium dose TSO; Drug: High dose TSO; Drug: Placebo</intervention_summary>
    <last_changed>February 9, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>339</order>
    <score>0.90217</score>
    <nct_id>NCT01266785</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01266785</url>
    <title>Infliximab, Regulatory T Cells, IL2 and Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Infliximab</intervention_summary>
    <last_changed>July 20, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>340</order>
    <score>0.90214</score>
    <nct_id>NCT03105128</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03105128</url>
    <title>A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: placebo for risankizumab; Drug: risankizumab IV; Drug: risankizumab SC</intervention_summary>
    <last_changed>April 4, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>341</order>
    <score>0.90199</score>
    <nct_id>NCT01555437</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01555437</url>
    <title>Assessment of Capsule Endoscopy Scoring Index (CESI), Harvey-Bradshaw Index (HBI) and Biological Markers in Small Bowel Crohn's Disease (SBCD)</title>
    <status open="N">Completed</status>
    <condition_summary>Small Bowel Crohn's Disease</condition_summary>
    <last_changed>November 18, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>342</order>
    <score>0.9018</score>
    <nct_id>NCT02897661</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02897661</url>
    <title>Fecal Microbiota Transplantation Improves Nutritional State of Patients With Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Diseases</condition_summary>
    <intervention_summary>Procedure: FMT; Drug: Metronidazole; Dietary Supplement: EN</intervention_summary>
    <last_changed>January 26, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>343</order>
    <score>0.90175</score>
    <nct_id>NCT01369667</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01369667</url>
    <title>Vitamin D Supplementation in Adult Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Vitamin D3; Other: Placebo</intervention_summary>
    <last_changed>August 15, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>344</order>
    <score>0.9016</score>
    <nct_id>NCT01752790</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01752790</url>
    <title>Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Pediatric Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Top-down; Drug: Step-up</intervention_summary>
    <last_changed>March 5, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>345</order>
    <score>0.90143</score>
    <nct_id>NCT00705614</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00705614</url>
    <title>Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Remicade</intervention_summary>
    <last_changed>February 17, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>346</order>
    <score>0.9013</score>
    <nct_id>NCT02852694</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02852694</url>
    <title>Reduce Risk for Crohn's Disease Patients</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Methotrexate; Drug: Adalimumab; Drug: Azathioprine / 6 Mercaptopurine</intervention_summary>
    <last_changed>July 24, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>347</order>
    <score>0.90122</score>
    <nct_id>NCT01881490</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01881490</url>
    <title>The ImageKids Study: Developing the pMEDIC and the PICMI</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Device: MRE</intervention_summary>
    <last_changed>April 27, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>348</order>
    <score>0.90055</score>
    <nct_id>NCT01291810</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01291810</url>
    <title>Clinical Efficacy of TNFa Kinoid in Crohn's Disease Patients</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: TNF Kinoid; Biological: WFI</intervention_summary>
    <last_changed>September 17, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>349</order>
    <score>0.9005</score>
    <nct_id>NCT02764762</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02764762</url>
    <title>Triple Combination Therapy in High Risk Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab; Drug: Adalimumab; Drug: Methotrexate</intervention_summary>
    <last_changed>April 6, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>350</order>
    <score>0.90044</score>
    <nct_id>NCT00546546</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00546546</url>
    <title>Early Immunosuppressants in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: early immunosuppressants (azathioprine, methotrexate)</intervention_summary>
    <last_changed>April 26, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>351</order>
    <score>0.90044</score>
    <nct_id>NCT01487759</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01487759</url>
    <title>Prebiotic Effect on Metabolites in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Oligofructose enriched inulin; Dietary Supplement: Maltodextrin</intervention_summary>
    <last_changed>December 9, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>352</order>
    <score>0.90043</score>
    <nct_id>NCT02675153</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02675153</url>
    <title>To Evaluate the Efficacy and Safety of Sirolimus for Crohn's Disease With Stenosis</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Diseases</condition_summary>
    <intervention_summary>Drug: Sirolimus; Drug: 5-ASA, Prednisone, Azathioprine or Remicade</intervention_summary>
    <last_changed>June 6, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>353</order>
    <score>0.9004</score>
    <nct_id>NCT03150238</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03150238</url>
    <title>Surgically Resected Crohn's Disease Patients: Prognostic Factors for Re-operation and New Score Building</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Other: observation of prognostic factors for relapse</intervention_summary>
    <last_changed>May 11, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>354</order>
    <score>0.90022</score>
    <nct_id>NCT00409617</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00409617</url>
    <title>Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: adalimumab; Biological: adalimumab</intervention_summary>
    <last_changed>October 6, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>355</order>
    <score>0.89991</score>
    <nct_id>NCT01891214</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01891214</url>
    <title>Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for Ulcerative Colitis and Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <intervention_summary>Other: Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)</intervention_summary>
    <last_changed>February 14, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>356</order>
    <score>0.89989</score>
    <nct_id>NCT00179842</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00179842</url>
    <title>Immune Ablation and Stem Cell Support for Crohn's Disease</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Procedure: Stem Cell Transplant</intervention_summary>
    <last_changed>September 21, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>357</order>
    <score>0.89983</score>
    <nct_id>NCT02453607</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02453607</url>
    <title>The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Inflammatory Bowel Disease; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Infliximab; Drug: thiopurine</intervention_summary>
    <last_changed>February 14, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>358</order>
    <score>0.89982</score>
    <nct_id>NCT00038766</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00038766</url>
    <title>CNI-1493 for Treatment of Moderate to Severe Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: semapimod; Drug: semapimod; Drug: placebo</intervention_summary>
    <last_changed>August 22, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>359</order>
    <score>0.89981</score>
    <nct_id>NCT01442025</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01442025</url>
    <title>Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Infliximab; Drug: Infliximab; Drug: Infliximab</intervention_summary>
    <last_changed>August 10, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>360</order>
    <score>0.89956</score>
    <nct_id>NCT01540942</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01540942</url>
    <title>Impact of Disease Activity and Nutrition Treat on Postoperative Recurrence and Complications After Bowel Resection for Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Dietary Supplement: nutrition treat; Other: surgery</intervention_summary>
    <last_changed>March 20, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>361</order>
    <score>0.89952</score>
    <nct_id>NCT00364130</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00364130</url>
    <title>Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Device: Low magnitude mechanical stimulus; Device: Placebo (inactive) low magnitude mechanical stimulus</intervention_summary>
    <last_changed>March 17, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>362</order>
    <score>0.89945</score>
    <nct_id>NCT00094458</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00094458</url>
    <title>Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Biological: infliximab infusion; AZA placebo caps; Other: infliximab (IFX) infusion; azathioprine (AZA) caps; Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps</intervention_summary>
    <last_changed>December 15, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>363</order>
    <score>0.8994</score>
    <nct_id>NCT01215890</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01215890</url>
    <title>Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Low Bone Mineral Density</condition_summary>
    <intervention_summary>Drug: risedronate; Drug: placebo</intervention_summary>
    <last_changed>October 5, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>364</order>
    <score>0.89933</score>
    <nct_id>NCT01624376</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01624376</url>
    <title>Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Fistulizing Crohn's Disease</condition_summary>
    <intervention_summary>Drug: DLX105; Drug: Placebo</intervention_summary>
    <last_changed>February 3, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>365</order>
    <score>0.89932</score>
    <nct_id>NCT01622270</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01622270</url>
    <title>Energy Expenditure in Patients With Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Indirect calorimetry, body composition , blood tests,3 days food records,Crohns disease activity index</intervention_summary>
    <last_changed>June 14, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>366</order>
    <score>0.89923</score>
    <nct_id>NCT02341755</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02341755</url>
    <title>Dual Energy Computerized Tomography (DE-CT) in Patients With Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>January 16, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>367</order>
    <score>0.89919</score>
    <nct_id>NCT02010762</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02010762</url>
    <title>The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vitamin D; Drug: Placebo</intervention_summary>
    <last_changed>January 13, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>368</order>
    <score>0.89911</score>
    <nct_id>NCT02186275</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02186275</url>
    <title>The Vitamin D in Pediatric Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day; Drug: Vitamin D3 800 UI/day then 800 UI/day</intervention_summary>
    <last_changed>May 17, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>369</order>
    <score>0.8991</score>
    <nct_id>NCT00072839</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00072839</url>
    <title>Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: ALX-0600; Drug: placebo; Drug: teduglutide 0.05; Drug: teduglutide 0.2 mg; Drug: Teduglutide 0.05 dose; Drug: teduglutide 0.1 mg dose</intervention_summary>
    <last_changed>November 10, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>370</order>
    <score>0.89907</score>
    <nct_id>NCT02646683</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02646683</url>
    <title>A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: vedolizumab</intervention_summary>
    <last_changed>July 4, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>371</order>
    <score>0.89894</score>
    <nct_id>NCT02501291</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02501291</url>
    <title>Thalidomide in Treating Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Thalidomide</intervention_summary>
    <last_changed>February 29, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>372</order>
    <score>0.89885</score>
    <nct_id>NCT02615288</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02615288</url>
    <title>High Dose Vitamin D3 in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Vitamin D3</intervention_summary>
    <last_changed>November 24, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>373</order>
    <score>0.89877</score>
    <nct_id>NCT00543374</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00543374</url>
    <title>Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Placebo; Drug: PROCHYMAL adult human mesenchymal stem cells</intervention_summary>
    <last_changed>October 12, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>374</order>
    <score>0.89849</score>
    <nct_id>NCT03169894</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03169894</url>
    <title>Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: MDGN-002</intervention_summary>
    <last_changed>July 25, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>375</order>
    <score>0.89842</score>
    <nct_id>NCT01444092</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01444092</url>
    <title>Safety Study of Entocort for Children With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Entocort</intervention_summary>
    <last_changed>November 16, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>376</order>
    <score>0.8983</score>
    <nct_id>NCT00032799</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00032799</url>
    <title>Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: natalizumab</intervention_summary>
    <last_changed>June 14, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>377</order>
    <score>0.8983</score>
    <nct_id>NCT03172377</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03172377</url>
    <title>Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease in Remission; Crohn Disease</condition_summary>
    <intervention_summary>Other: Lengthening adalimumab dosing interval</intervention_summary>
    <last_changed>May 29, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>378</order>
    <score>0.8983</score>
    <nct_id>NCT01290042</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01290042</url>
    <title>Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.</title>
    <status open="N">Completed</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: AMG 181; Other: Placebo for AMG 181</intervention_summary>
    <last_changed>March 12, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>379</order>
    <score>0.89806</score>
    <nct_id>NCT00032786</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00032786</url>
    <title>Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: natalizumab</intervention_summary>
    <last_changed>June 14, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>380</order>
    <score>0.89802</score>
    <nct_id>NCT02177071</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02177071</url>
    <title>A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: INFLIXIMAB; Drug: AZATHIOPRINE; Drug: MERCAPTOPURINE; Drug: Methotrexate</intervention_summary>
    <last_changed>May 4, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>381</order>
    <score>0.89789</score>
    <nct_id>NCT00252369</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00252369</url>
    <title>Treatment of Perianal Crohn's Disease, Combining Medical and Surgical Treatment.</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Infliximab; Procedure: Instillation of fibrin glue</intervention_summary>
    <last_changed>April 23, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>382</order>
    <score>0.89779</score>
    <nct_id>NCT02256462</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02256462</url>
    <title>Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Adalimumab</intervention_summary>
    <last_changed>July 1, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>383</order>
    <score>0.89777</score>
    <nct_id>NCT00724958</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00724958</url>
    <title>Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Infliximab</intervention_summary>
    <last_changed>October 1, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>384</order>
    <score>0.89777</score>
    <nct_id>NCT02765256</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02765256</url>
    <title>Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Fluconazole; Drug: Vancomycin; Drug: Neomycin; Drug: Ciprofloxacin; Drug: Polyethylene Glycol 3350; Drug: Promethazine</intervention_summary>
    <last_changed>July 5, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>385</order>
    <score>0.89776</score>
    <nct_id>NCT01470599</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01470599</url>
    <title>A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: CP-690,550; Drug: CP-690,550</intervention_summary>
    <last_changed>February 22, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>386</order>
    <score>0.89761</score>
    <nct_id>NCT02976129</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02976129</url>
    <title>A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: V565; Drug: Placebo</intervention_summary>
    <last_changed>July 14, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>387</order>
    <score>0.89748</score>
    <nct_id>NCT02164877</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02164877</url>
    <title>Effect of Soluble Dietary Fiber on Bacterial Translocation in Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: pectin</intervention_summary>
    <last_changed>June 13, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>388</order>
    <score>0.89744</score>
    <nct_id>NCT01556672</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01556672</url>
    <title>Adalimumab-psoriasis and Small Bowel Lesions</title>
    <status open="N">Completed</status>
    <condition_summary>Plaque Psoriasis; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Adalimumab; Device: Capsule endoscopy</intervention_summary>
    <last_changed>June 28, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>389</order>
    <score>0.89742</score>
    <nct_id>NCT01809275</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01809275</url>
    <title>Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Inflammatory Bowel Disease</condition_summary>
    <intervention_summary>Drug: QBECO; Drug: Placebo</intervention_summary>
    <last_changed>August 19, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>390</order>
    <score>0.89728</score>
    <nct_id>NCT00838149</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00838149</url>
    <title>Effect of Glutamine on Intestinal Permeability in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Glutamine; Dietary Supplement: Whey protein</intervention_summary>
    <last_changed>February 5, 2009</last_changed>
  </clinical_study>
  <clinical_study>
    <order>391</order>
    <score>0.89715</score>
    <nct_id>NCT02896985</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02896985</url>
    <title>Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>May 10, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>392</order>
    <score>0.89706</score>
    <nct_id>NCT01836289</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01836289</url>
    <title>High-dose Cyclophosphamide for Severe Refractory Crohn Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Crohn Disease</condition_summary>
    <intervention_summary>Drug: High-dose Cyclophosphamide</intervention_summary>
    <last_changed>March 1, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>393</order>
    <score>0.89694</score>
    <nct_id>NCT00300118</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00300118</url>
    <title>Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: budesonide; Drug: mesalazine</intervention_summary>
    <last_changed>May 16, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>394</order>
    <score>0.89682</score>
    <nct_id>NCT00946361</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00946361</url>
    <title>Impaired Insulin-like Growth Factor-1 (IGF-1) Generation Causes Protein Catabolism and Poor Growth in Children With Crohn Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohns Disease</condition_summary>
    <intervention_summary>Other: Examinations</intervention_summary>
    <last_changed>May 14, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>395</order>
    <score>0.89679</score>
    <nct_id>NCT00055497</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00055497</url>
    <title>Remission in Subjects With Crohn's Disease, 1 Year Phase</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Double-blind (DB) adalimumab placebo; Biological: DB adalimumab 40 mg eow; Biological: DB adalimumab 40 mg ew; Biological: OL adalimumab 40 mg</intervention_summary>
    <last_changed>April 7, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>396</order>
    <score>0.89665</score>
    <nct_id>NCT02914561</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02914561</url>
    <title>Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Filgotinib; Drug: Placebo to match filgotinib</intervention_summary>
    <last_changed>August 2, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>397</order>
    <score>0.89621</score>
    <nct_id>NCT00705471</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00705471</url>
    <title>Impact of Infliximab in Fistulizing Crohn's Disease on Health Care Resources (Study P04204)(TERMINATED)</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Biological: Infliximab</intervention_summary>
    <last_changed>April 7, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>398</order>
    <score>0.89621</score>
    <nct_id>NCT01231217</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01231217</url>
    <title>Green Tea in Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Green tea (Camellia sinensis); Other: Coffee</intervention_summary>
    <last_changed>October 29, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>399</order>
    <score>0.89612</score>
    <nct_id>NCT01224171</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01224171</url>
    <title>Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: vedolizumab; Other: Placebo</intervention_summary>
    <last_changed>June 19, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>400</order>
    <score>0.89608</score>
    <nct_id>NCT01582568</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01582568</url>
    <title>EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohns Disease</condition_summary>
    <intervention_summary>Drug: Certolizumab</intervention_summary>
    <last_changed>February 17, 2016</last_changed>
  </clinical_study>
</search_results>
